TRIB Trinity Biotech plc
Price Chart
Executive Summary
Trinity Biotech announced successful clinical validation of an enhanced version of its EpiCapture™ prostate cancer test, which now incorporates machine learning and patient ethnicity to improve risk prediction accuracy. The test achieved an 85% AUC in a 750-patient study and will be commercialized as a lab-developed test through its New York reference lab, marking the company's strategic entry into precision oncology diagnostics.
Actionable Insight
Traders should monitor upcoming commercial launch timelines and potential payer reimbursement strategies for EpiCapture™, as successful adoption could significantly impact revenue given the large prostate cancer testing market. The 85% AUC is clinically compelling and may drive rapid physician adoption.
Key Facts
- Enhanced EpiCapture™ test achieved 85% clinical accuracy (AUC) in a 750-patient clinical study.
- Test integrates machine learning and patient ethnicity with DNA biomarkers for improved risk prediction of aggressive prostate cancer.
- Will be commercialized as a Laboratory Developed Test (LDT) through Trinity Biotech’s New York reference laboratory.
- Represents Trinity Biotech’s first entry into precision oncology diagnostics.
- Test offers a non-invasive urine-based alternative to MRI and needle biopsy.
Financial Impact
Potential new revenue stream in precision oncology; exact financial impact not quantified but strategically significant given $20B U.S. prostate cancer care market.
Risk Factors
- Commercialization success depends on market acceptance and physician adoption of a new diagnostic modality.
- Reimbursement challenges for a new LDT without established CPT coding or payer coverage.
- Execution risk in scaling lab operations in New York to handle nationwide volume.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260502 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
6d ago
|
F-1/A
| $0.6800 $0.6700 | ▲ +1.47% | ▼ −1.13% | $0.6800 (−0.00%) |
|
May 26, 2026
15d ago
|
EFFECT
| $0.6500 $0.6800 | ▼ −4.62% | ▼ −4.60% | $0.6800 (−4.62%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $0.6000 $0.6100 | ▲ +1.67% | ▲ +2.02% | $0.6800 (+13.33%) |
|
Mar 4, 2026
14w ago
|
EFFECT
| $0.7000 $0.7300 | ▲ +4.29% | ▲ +4.86% | $0.6800 (−2.86%) |
|
Feb 25, 2026
14w ago
|
F-1
| $0.7500 $0.7200 | ▲ +4.00% | ▲ +3.45% | $0.6800 (+9.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access